ALLAKOS INC (ALLK)
US01671P1003 - Common Stock
ALLK gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. While ALLK seems to be doing ok healthwise, there are quite some concerns on its profitability. ALLK has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year ALLK has reported negative net income.
In the past year ALLK has reported a negative cash flow from operations.
ALLK had negative earnings in each of the past 5 years.
ALLK had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -143.65%, ALLK is doing worse than 84.32% of the companies in the same industry.
ALLK's Return On Equity of -245.72% is on the low side compared to the rest of the industry. ALLK is outperformed by 70.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -143.65% | ||
| ROE | -245.72% | ||
| ROIC | N/A |
ROA(3y)-69.83%
ROA(5y)-49.47%
ROE(3y)-91.22%
ROE(5y)-62.87%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ALLK so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for ALLK has been increased compared to 1 year ago.
ALLK has more shares outstanding than it did 5 years ago.
ALLK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -16.12, we must say that ALLK is in the distress zone and has some risk of bankruptcy.
ALLK's Altman-Z score of -16.12 is on the low side compared to the rest of the industry. ALLK is outperformed by 84.32% of its industry peers.
ALLK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.12 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 6.08 indicates that ALLK has no problem at all paying its short term obligations.
ALLK has a Current ratio of 6.08. This is in the better half of the industry: ALLK outperforms 61.26% of its industry peers.
A Quick Ratio of 6.08 indicates that ALLK has no problem at all paying its short term obligations.
ALLK's Quick ratio of 6.08 is fine compared to the rest of the industry. ALLK outperforms 61.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.08 | ||
| Quick Ratio | 6.08 |
3. Growth
3.1 Past
ALLK shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.73%.
EPS 1Y (TTM)-5.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 15.22% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y27.46%
EPS Next 2Y31.5%
EPS Next 3Y18.76%
EPS Next 5Y15.22%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ALLK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALLK. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ALLK's earnings are expected to grow with 18.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.5%
EPS Next 3Y18.76%
5. Dividend
5.1 Amount
ALLK does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ALLAKOS INC
NASDAQ:ALLK (1/6/2025, 5:20:00 PM)
After market: 1.1301 +0.06 (+5.62%)1.07
-0.09 (-7.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners88.1%
Inst Owner Change0%
Ins Owners1.47%
Ins Owner Change-5.64%
Market Cap95.59M
Analysts73.85
Price Target3.42 (219.63%)
Short Float %0.96%
Short Ratio1.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.35%
Min EPS beat(2)11.48%
Max EPS beat(2)17.22%
EPS beat(4)2
Avg EPS beat(4)-22.01%
Min EPS beat(4)-69.86%
Max EPS beat(4)17.22%
EPS beat(8)5
Avg EPS beat(8)-8.62%
EPS beat(12)6
Avg EPS beat(12)-12.4%
EPS beat(16)8
Avg EPS beat(16)-10.17%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)16.32%
PT rev (3m)20.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.24%
EPS NY rev (1m)-0.21%
EPS NY rev (3m)1.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.31 | ||
| P/tB | 1.31 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.03
EYN/A
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0
BVpS0.81
TBVpS0.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -143.65% | ||
| ROE | -245.72% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-69.83%
ROA(5y)-49.47%
ROE(3y)-91.22%
ROE(5y)-62.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.63% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.08 | ||
| Quick Ratio | 6.08 | ||
| Altman-Z | -16.12 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)521.85%
Cap/Depr(5y)331.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.62%
EPS Next Y27.46%
EPS Next 2Y31.5%
EPS Next 3Y18.76%
EPS Next 5Y15.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.21%
EBIT Next 3Y18.72%
EBIT Next 5Y26.45%
FCF growth 1Y67.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.7%
OCF growth 3YN/A
OCF growth 5YN/A